A Phase 1, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Antitumor Activity of MH048 in Subjects With Selected Relapsed/Refractory B-cell Malignancies
Latest Information Update: 06 Oct 2023
Price :
$35 *
At a glance
- Drugs MH 048 (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Small cell lung cancer
- Focus Adverse reactions
- Sponsors Minghui Pharmaceutical (Shanghai)
- 07 Jun 2022 Results (n=12) reporting efficacy and safety data from dose escalation portion of this trial presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 31 Aug 2021 Status changed from not yet recruiting to recruiting.
- 04 Jan 2021 New trial record